Table 1.

Comparative analysis of Cervarix and Gardasil vaccine against HPV infection.

Features	Cervarix	Gardasil	Gardasil 9	References
Manufacturer	GlaxoSmithKline	Merck & Co.	Merck & Co.	(41, 42)
Valence	Bivalent	Quadrivalent	9 valent	(41, 42)
VLP types	16, 18	6, 11, 16, 18	6, 11, 16, 18, 31, 33, 45, 52, 58	(42–44)
Protection rate against cervical cancer	70%	70%–75%	90%	(42–44)
Adjuvant	MPL absorbed on aluminum hydroxide (AS04)	aluminum hydroxyphosphate sulfate	aluminum hydroxyphosphate sulfate	(45–47)
Expression system	Baculovirus-insect cell	Saccharomyces cerevisiae	Saccharomyces cerevisiae	(45, 46)
Cross protection	HPV33, 35	HPV31	Unknown	(48, 49)
Sustenance of vaccine efficiency	11 years	10 years	6 years	(50–52)
Adverse effects (AEs)	Localized pain at injection site, inflammation	Localized pain, edema, Muscular pain, dysentery, fever, vomiting	Pain at the localised site, swelling	(53)